-

Circulation Publishes Data Validating Vektor Medical’s Non-invasive Heart Mapping Technology Using Only 12-lead ECG

Study shows 97.3% accuracy in identifying arrhythmia source locations in nine atrial and ventricular arrhythmias and pacing types across all four heart chambers.

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, the developer of the world’s first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, today announced Circulation: Arrhythmia and Electrophysiology has published a peer-reviewed manuscript of the clinical data from a study evaluating the accuracy of its vMap® technology. The system, which was cleared by the U.S. Food and Drug Administration in November 2021, demonstrated high accuracy for vMap in identifying arrhythmia sources throughout the heart.

The mapping system uses the information found in a 12-lead ECG and provides physicians with accurate and actionable insights to treat cardiac arrhythmias. The easy-to-use and non-invasive technology aims to improve first-pass ablation success, lower risks from invasive mapping and long fluoroscopy exposure, and reduce procedure times, all of which are expected to reduce healthcare costs associated with ablation.

The article titled Forward-Solution Noninvasive Computational Arrhythmia Mapping: The VMAP Study” was authored by researchers and cardiologists at the Department of Medicine at the University of California San Diego, Veterans Affairs San Diego Healthcare System, Mills Peninsula Medical Center, Medical University of South Carolina, Katherine Kacena Consulting, Technomics Research, the Department of Bioengineering at the University of California San Diego, and Vektor Medical, Inc.

The blinded, multicenter, independently-adjudicated study compared the accuracy of vMap in identifying source locations of seven atrial and ventricular arrhythmias, as well as atrial and ventricular pacing to arrhythmia sources identified during the invasive electrophysiology study. System accuracy exceeded pre-specified performance goals in the primary and secondary endpoints:

  1. Regional accuracy for ventricular tachycardia (VT) and premature ventricular complexes (PVC) without structural heart disease and ventricular scar burden <10% (primary endpoint) was 98.7% (74/75 cases, 95% CI: 96.0 - 100%, p<0.001 to reject predefined null hypothesis).
  2. For all enrolled cases (which includes atrial and ventricular fibrillation), regional accuracy (secondary endpoint 1) was 96.9% (247/255 cases, 95% CI: 94.7 - 99.0%, p<0.001 to reject predefined null hypothesis).
  3. Accuracy for all enrolled cases in identifying the exact or neighboring segments (secondary endpoint 2) was 97.3% (248/255 cases, 95% CI: 95.2-99.3%, p<0.001 to reject predefined null hypothesis).
  4. Center-to-center absolute spatial accuracy across all arrhythmia subgroups was 15 mm [Interquartile range: 7–25 mm].
  5. The median analysis time from ECG data upload into the system and ending with display of the mapping results was 0.8 minutes (IQR: 0.4–1.4 minutes).

“Results of the vMap study surpassed our expectations and serve as further evidence of vMap’s potential to improve ablation success, reduce risk, and shorten procedure time,” said David Krummen, M.D., FACC, FHRS, co-founder and inventor of Vektor Medical. “We have created this technology with the goal of positively impacting millions of people suffering from cardiac arrhythmias.”

Traditional arrhythmia mapping is often labor- and time-intensive, frequently requiring fluoroscopy for intracardiac navigation. vMap aims to improve first-pass ablation success, lower risks from invasive mapping and fluoroscopy exposure, and reduce procedure times. The system may also be used to guide stereotactic ablative radiotherapy for refractory ventricular arrhythmias. These features together are expected to improve arrhythmia care and reduce healthcare costs associated with targeted arrhythmia therapy.

The abstract from Vektor’s clinical validation study was presented by Dr. David Krummen at Heart Rhythm 2022. The company is currently rolling out the technology at select cardiovascular centers across the country.

About vMap

vMap is designed to quickly, easily, and non-invasively map arrhythmia sources associated with focal- or fibrillation- type arrhythmias in all cardiac chambers, septum, and outflow tracts. The easy-to-use system takes less than three minutes for a clinician to input case information, upload and markup an ECG, and receive a 3D interactive arrhythmia source location map visualizing the inside and outside of the heart.

About Vektor Medical

San Diego-based Vektor Medical, Inc. is the developer of the world’s first FDA-cleared forward-solution arrhythmia mapping technology to rapidly identify arrhythmia source locations using only 12-lead ECG data. This data is analyzed using proprietary computational modeling to create actionable 2D and 3D cardiac arrhythmia source probability maps. The company’s advanced, non-invasive cardiac arrhythmia mapping platform aims to improve the care of cardiac arrhythmias worldwide.

Contacts

Gaelin White
Health+Commerce
(949) 257-3544
gaelin@healthandcommerce.com

Vektor Medical


Release Versions

Contacts

Gaelin White
Health+Commerce
(949) 257-3544
gaelin@healthandcommerce.com

Social Media Profiles
More News From Vektor Medical

CORRECTING and REPLACING Heart Rhythm Case Reports Publishes Notable Case Detailing First Use of AI-Guided ECG Mapping for Left Bundle Branch Area Pacing

SAN DIEGO--(BUSINESS WIRE)--In the release dated April 1, 2025, the quote from, and photo of, Dr. Ulrika Birgersdotter-Green has been removed. The updated release reads: HEART RHYTHM CASE REPORTS PUBLISHES NOTABLE CASE DETAILING FIRST USE OF AI-GUIDED ECG MAPPING FOR LEFT BUNDLE BRANCH AREA PACING Case Report Demonstrates How vMap Enhances Accuracy and Reduces Risk in Pacemaker Implantation Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the...

Vektor Medical Strengthens Leadership Team to Accelerate Commercial Growth and Market Expansion

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced key leadership appointments to support commercial expansion and market entry initiatives. Michael Andersen has joined the company as Vice President, Sales, and Mihir Naik has been promoted to Vice President, Quality Assurance and Regulatory Affairs. These key moves position Vektor for rapid growth following its recently oversubscribed $25M Series A funding round. “The...

Vektor Medical Announces 2024 Milestones: A Year of Growth, Innovation, and Impact

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, is proud to announce key milestones achieved throughout 2024, underscoring a year defined by accelerated growth, technological innovation, and meaningful clinical impact. From the widespread adoption of vMap to groundbreaking clinical data and enhanced reimbursement pathways, Vektor Medical remains steadfast in its mission to transform arrhythmia care. Accelerated Adoption of vMap Ac...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.